Biopharmaceutical company Adcytherix, specializing in next-gen antibody drug conjugates, launched with €30M seed funding from top-tier investors.

Adcytherix, a biopharmaceutical company specializing in next-gen antibody drug conjugates (ADCs) for high unmet need diseases like cancer, launched with €30M seed funding. Founded by the Emergence Therapeutics team, it's backed by top-tier investors including Pontifax, Pureos Bioventures, RA Capital Management, and KKR-controlled Dawn Biopharma. The company aims to establish itself as a leading ADC developer.

June 11, 2024
3 Articles

Further Reading